

## Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997–2016 An observational study

Jongmin Sim, MD, PhD<sup>a</sup>, Takuya Takayama<sup>a,c</sup>, Junhun Cho, MD, PhD<sup>a</sup>, Seok Jin Kim, MD, PhD<sup>b</sup>, Won Seog Kim, MD, PhD<sup>b</sup>, Howe J. Ree, MD, PhD<sup>a</sup>, Young Hyeh Ko, MD, PhD<sup>a,\*</sup>

#### Abstract

The purpose of this study was to evaluate changes in the proportion of lymphoid neoplasm subtypes in South Korea. A total of 8615 cases of lymphoid neoplasms diagnosed in 1997–2016 at Samsung Medical Center in South Korea were classified according to the 2008 World Health Organization system. The total number and proportion of lymphoid neoplasms were compared between these two decades, with data from nationwide studies, and with other countries. To evaluate changes in the proportion of subtypes, crude rate of each subtype per 100 lymphoma patients during each decade and age adjusted rate were calculated. There were 3024 patients with lymphoid neoplasm in 1997–2006, and 5591 in 2007–2016, which represents an average increase of 1.85 times over the 20-year study period. Crude rate and age adjusted rate were increased in Hodgkin's lymphoma and mature B cell lymphoma while precursor lymphoid neoplasms and mature T cell lymphoma were decreased. Among B cell neoplasms, age adjusted rate of plasma cell neoplasm, follicular lymphoma, mantle cell lymphoma increased while there was no significant change in extranodal marginal zone lymphoma and Burkitt lymphoma. The increase in follicular lymphoma was due to the increases in nodal follicular lymphoma of low grade and duodenal-type follicular lymphoma. These results are consistent with the dynamics of causative factors, including socioeconomic factors, in Korea.

**Abbreviations:** CLL/SLL = chronic lymphocytic leukemia/small lymphocytic lymphoma, EBV = Epstein–Barr virus, ENMZL = extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, FISH = fluorescence in situ hybridization, HTLV-1 = human T-cell leukemia virus type 1, KNCIDB = the Korean National Cancer Incidence Database, KSP = the Korean Society of Pathologists, MZL = marginal zone lymphoma, PTCL, NOS = peripheral T cell lymphoma, not otherwise specified, WHO = World Health Organization.

Keywords: epidemiology, hematologic neoplasms, incidence, Korea

## 1. Introduction

Lymphoid malignancy is a heterogeneous cancer group consisting of neoplastic lymphoid cells showing various morphologic

#### Editor: Leyi Wang.

This study was supported by a grant from the National Research Foundation of Korea (Grant No. NRF-2017R1A2B1010739).

We have no conflict of interest.

Supplemental Digital Content is available for this article.

<sup>a</sup> Department of Pathology and Translational Genomics, <sup>b</sup> Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, <sup>c</sup> University of the Ryukyus School of Medicine, Okinawa, Japan.

<sup>\*</sup> Correspondence: Young Hyeh Ko, Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea (e-mail: yhko310@skku.edu).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Sim J, Takayama T, Cho J, Kim SJ, Kim WS, Ree HJ, Ko YH. Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997–2016. Medicine 2019;98:45 (e17641).

Received: 7 February 2019 / Received in final form: 9 August 2019 / Accepted: 24 September 2019

http://dx.doi.org/10.1097/MD.000000000017641

and immunophenotypic findings corresponding to lymphocytes at various stages of lymphocyte differentiation. The origin, etiology, clinical features, and response to therapy of lymphoid neoplasms are highly diverse. The World Health Organization (WHO) classification recognizes more than 50 lymphoid neoplasm subtypes based on their unique clinical, histologic, immunophenotypic, and genetic findings.<sup>[1,2]</sup>

Lymphoid malignancy represents 8.3% of all cancers, according to 2018 SEER data.<sup>[3]</sup> In Korea, lymphoid malignancies account for 65%~70% of all blood cancers,<sup>[4,5]</sup> with approximately 8900 new patients and 4100 deaths annually.<sup>[5,6]</sup> Currently, the incidence of lymphoid tumors is gradually increasing in both Western and Asian countries, possibly attributable to socioeconomic and environmental factors that can modulate immune function and increase exposure to carcinogens.<sup>[7-9]</sup> Korea has been through industrialization from the 1960s to the 1980s and achieved a significant degree of socioeconomic improvement similar to that of other developed countries, resulted in considerable changes in quality of life, eating habits, and population distribution.<sup>[10]</sup> Such social and environmental changes may also lead to changes in the incidence of lymphoid neoplasms and their subtypes. It is well known that subtype incidences of malignant lymphoma differ according to geographic region, as well as among countries in the same geographic region.[11-15] Compared with Western countries, Asian countries have been reported to have higher rates of T/NKcell neoplasms and lower incidences of follicular lymphoma and

Hodgkin lymphoma. Epstein–Barr virus (EBV)-associated extranodal NK/T cell lymphoma, nasal type, is more frequent in Korea and China compared with Japan, where Human T-cell leukemia virus type 1 (HTLV-1)-associated adult T cell leukemia is prevalent.<sup>[16–19]</sup> In Korea, Helicobacter-associated extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (ENMZL) is a common lymphoid neoplasm subtype.<sup>[17,18]</sup>

Regarding the incidence of lymphoid neoplasm, some Korean studies using multicenter data have reported the incidence of lymphoid neoplasm of Korea, although these data have limitations, including the omission of liquid-phase lymphoid neoplasm.<sup>[8,12,18]</sup> The most recent data are based on a nationwide hospital-based cancer registry that covers all lymphoid malignancies, both liquid and solid phase, for 1999–2012. These data showed continuously increasing incidence of all lymphoid malignancies.<sup>[8]</sup> Two studies reported that follicular lymphoma is decreasing,<sup>[17,18]</sup> while another showed the opposite.<sup>[8]</sup> However, the frequency of extranodal NK/T-cell lymphoma was also reported in these two studies to be decreasing.<sup>[17,18]</sup>

To clarify the changing trends in the frequency of lymphoid neoplasm subtypes in Korea, we analyzed 8615 cases of lymphoid neoplasms diagnosed over 20 years at a single hospital. While our data are limited by having come from a single institution, relative to other studies, they also have the advantage that every case was reviewed by the authors (J Sim, YH Ko, HJ Ree) and included a large number of cases, representing 10% of the total lymphoma cases in the nation since 2012.

## 2. Materials and methods

## 2.1. Patients and tissue samples

All lymphoid neoplasms diagnosed in the solid organ at the Samsung Medical Center in 1997-2016 were retrieved from surgical pathology medical records in the department of pathology database using search terms "lymphoma," "lymphoproliferative disease," "lymphoproliferative disorders," "plasmacytoma," and "myeloma." All cases of lymphoid leukemia, lymphoma, and myeloma diagnosed in bone marrow and blood samples were also retrieved from the hospital medical records using ICD-O codes. All cases were diagnosed according to the 2008 WHO classification system, based on morphological, immunophenotypical, and clinical features. Cases diagnosed prior to the 2008 WHO classification system were reclassified according to the 2008 classification by the authors (J Sim, YH Ko, HJ Ree). Posttransplantation lymphoproliferative disorders and cases with insufficient immunohistochemical evidence to allow 2008 WHO classification were excluded. Only the initial diagnosis for each patient was included. A total of 8615 patients diagnosed with lymphoid neoplasms in 1997-2016 were enrolled. Age, gender, pathological diagnoses, and source of specimen were also obtained from the medical records. The study was approved by the Institutional Review Board of Samsung Medical Center (IRB File No. 2017-08-148-001).

## 2.2. Ancillary studies for diagnosis

For 2008 WHO classification, immunohistochemical staining was performed at diagnosis in all cases of lymphoma/plasma cell neoplasms diagnosed in solid organ and body fluid. Basically, immunostaining for B- and T-cell markers (CD3 [Dako, Santa Clara, CA, USA] and CD20 [Leica, Wetzlar, Germany]) were

performed in all cases. In cases requiring further immunophenotyping, additional markers such as CD1a, CD2, CD4 (Leica), CD5, CD7, CD8 (Leica), CD10 (Leica), CD15, CD21, CD23, CD30, CD34, CD56, CD57, CD68, CD79a, CD99, CD123, CD138, epithelial membrane antigen, cyclin D1, sox11, bcl2, bcl6, multiple myeloma oncogene 1 (MUM-1), PAX-5, TCRβF1, TCR-cγM1, T-cell restricted intracellular antigen-1 (TIA-1) (Immunotech, Marseille, France), granzyme B, ALK-1, myeloperoxidase, IgM, IgG, IgA, IgD (Thermo scientific, Waltham, MA, USA), kappa light chain, lambda light chain, (Dako), HHV-8, and terminal deoxyribonucleotidyl transferase (Dako) were used. To diagnose myeloma and leukemia in bone marrow, flow cytometric immunophenotyping was performed. Acute leukemia panel included cCD3, CD10, CD11c, CD13, CD14, CD19, CD20, cCD22, CD33, CD34, CD38, CD64, CD66c, cCD79a, CD117, cMPO, nTdT, and CD45. Multiple myeloma panel included CD19, CD38, CD138, CD45, CD56, CD117, CD28, kappa light chain, and lambda light chain.

EBV was detected by in situ hybridization using EBER (EBVencoded small nuclear small RNA) and quantitative EBV DNA analysis from blood samples. Clonality analysis was carried out using conventional PCR or BIOMED-2 Multiplex PCR for IgH gene, TCR- $\gamma$ , and  $\beta$  gene.<sup>[20]</sup> When necessary, C-MYC and Bcl-2 translocation were detected by fluorescence in situ hybridization (FISH).

#### 2.3. Statistical analyses

Crude rate for proportion of each subtype was determined as a frequency rate per 100 lymphoma patients during 1997–2006 and 2007–2016. Calculation of age adjusted rate used Korea's standard population in the year of 2000 (Statistics Korea, http://kostat.go.kr/portal/korea/index.action).

## 3. Results

#### 3.1. Demographics

The cases were 3740 females and 4875 male patients (M:F ratio 1.3:1) with a median age of 54 years (range: 0–96). Biopsy sites were lymph node (1774 cases, 20.6%), bone marrow (2233 cases, 25.9%), and extranodal sites (4608 cases, 53.5%), including (in descending frequency) stomach (1229 cases, 14.4%), upper aerodigestive tract (480 cases, 5.6%), intestine (478 cases, 5.5%), brain (308 cases, 3.6%), skin (256 cases, 3%), Waldeyer's ring (239 cases, 2.8%), and bone (208 cases, 2.4%) (Table 1; Supplementary Table 1, http://links.lww.com/MD/D318).

## 3.2. Subtype distribution of all lymphoid neoplasms

The 8615 cases were classified as Hodgkin lymphoma (329 cases, 3.8%), precursor lymphoid neoplasms (953 cases, 11.1%), mature B cell neoplasms (6242 cases, 72.5%), and mature T and NK cell neoplasms (1091 cases, 11.7%). All but six of the 329 Hodgkin lymphomas were classic type. Among the mature B cell neoplasms, frequent subtypes included (in descending frequency) diffuse large B cell lymphoma (2236 cases, 26.5%), ENMZL (1451 cases, 16.8%), plasma cell neoplasms (1379 cases, 15.2%), follicular lymphoma (397 cases, 4.9%), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (160 cases, 1.9%), Burkitt lymphoma (163 cases, 1.9%), and mantle cell lymphoma (136, 1.6%). Among the mature T and NK cell neoplasms, extranodal NK/T cell lymphoma, nasal-type, was the

## Table 1

## Distribution of histologic subtypes, age, and sex of 8615 patients with lymphoid neoplasm diagnosed between 1997 and 2016.

Displace         Inc.         14         Inc.         14         Inc.         14         Inc.           hadget hyperbox         379         3.8         1.3.1         32 6-9-3         Notlair 1P H         3         3.8         1.3.1         32 6-9-3         Notlair 1P H         3.8         1.3.1         32 6-9-3         Notlair 1P H         3.8         1.3.1         1.1         1.3.1         32 6-9-3         Notlair 1P H         3.8         1.3.1         1.1         1.3.1         31 6-3         1.3.1         1.1         1.9.7         1.3.1         1.1         1.2.1         1.1         1.3.1         1.1         1.2.1         1.1         1.2.1         1.1         1.2.1         1.1         1.2.1         1.1         1.2.1         1.1         1.2.1         1.1         1.2.1         1.1         1.2.1         1.1         1.2.2         1.3.1         1.1         1.2.2         1.3.1         1.1         1.2.2         1.3.1         1.1         1.2.2         1.3.1         1.1         1.2.2         1.3.1         1.1         1.2.2         1.3.1         1.1         1.2.2         1.3.1         1.1         1.2.2         1.3.1         1.1         1.2.1         1.3.1         1.1         1.2.1         1.3.1         1	Diagnosis		No		0/_	M·E	Age (years) Median (range)
Idal cases         BB15         IO0         1.31         B6 Id-469           Nodur IP H         6         0.1         5.1         44 (13-57)           Lassis H         323         3.7         1.7.1         32 (1-62)           Pinzars Inputodi incipism (B1)         B53         1.1.1         1.3.1         1.31         1.31         1.34           LR, NS         266         3.1         1.3.1         1.3         1.3         1.3         1.3           URL         RS         517         6.0         0.3         1.1         1.6         6.4         1.1         1.6         6.4         1.1         1.6         6.6         1.1         1.6         6.6         6.6         1.1         1.6         6.6         6.6         1.1         1.6         6.6         6.7         1.6         6.6         7.7         6.0         1.2         1.3         1.6         6.6         2.1         1.6         6.6         2.1         1.6         6.6         2.1         1.6         6.6         2.7         7.0         4.6         6.7         7.0         4.6         7.0         7.0         7.0         7.0         7.0         7.0         7.0         7.0         7.0         7.			NO.		70	IVI.I	
backges         magnetic properties         3.8         1.8.1         3.2.2         3.7         1.7.1         3.2.6         4.4         (13-6)           Classic II.         B53         11.1         1.3.1         11.0         1.3.6         4.0         (13-6)         1.1.1         1.3.1         11.0         6.0         1.0.1         11.0         1.0.1         10.0         7.7         1.2.1         10.0         7.7         1.2.1         10.0         7.7         1.2.1         10.0         7.7         1.2.1         10.0         7.7         1.0.1         10.0         7.7         1.0.1         10.0         10.0         1.0	lotal cases	8615			100	1.3:1	56 (0-96)
boots         Precurs of purploid negation (LBL)         95         0.1         5.7         4.4         15-67           Precurs of purploid negation (LBL)         953         11.1         1.3.1         13         6-80           LBL, NS         266         3.1         1.3.1         11         10-73           LBL, PB         517         6.6         1.0.1         11         6-73           LBL, PB         100         1.9         1.6.1         6.6         1.9           Denote hymphotopic lealemine         6242         72.5         1.2.1         68         1.9           Denote hymphotopic lealemine         5         0.1         6.1         1.6         1.6         2.1         48         1.6           Denote hymphotopic lealemine         5         0.1         6.1         1.6	Hodgkin lymphoma (HL)	329			3.8	1.8:1	32 (6–92)
Lasse int.         323         3.7         1.7         32 (9-49)           Pecuard Introbutic neptism (LBL)         953         11.1         1.3.1         11.0         17.0         2.0         2.3.1         11.1         10.7-78)           LBL P         170         2.0         2.3.1         10.7-78)         12.1         10.6         10.9         16.1         10.7         10.6         10.9         10.6         10.9         10.6         10.9         10.6         10.9         10.6         10.9         10.6         10.2         10.4         10.6         10.2-79)         10.8         10.6         10.2-79)         10.8         10.6         10.7         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6         10.7-83)         10.6	Nodular LP HL		6		0.1	5:1	44 (13-67)
Precision integrisem (Ed.)         93.5         11.1         1.3.1         1.3.1         1.0         -7.8           LBL, NOS         266         3.1         1.3.1         1.1         0.7.1         1.0         7.9           LB, -T         170         2.0         2.3.1         1.0         1.0         7.9         1.0         7.0         2.0         2.3.1         1.0         1.0         1.0         7.0         2.0         2.3.1         1.0         1.0         7.0         2.0         2.3.1         1.0         1.0         4.0         2.0         2.3.1         1.0         7.0         2.0         3.0         2.0         3.0         2.0         3.0         2.0         3.0         2.0         3.0         1.0         7.0         1.4         3.0         2.0         1.0         1.0         2.0         1.0         1.0         3.0         0.0         3.0         0.0         3.0         1	Classic HL	050	323		3.7	1.7:1	32 (6-92)
LBC, MOS         260         3.1         1.3.1         11 (0-78)           LBC-1         770         2.0         2.3.1         10 (1-78)           LBC-1         770         2.0         2.3.1         10 (1-78)           LBC-1         770         2.0         2.3.1         10 (1-78)           Chronic implicity implic	Precursor lymphoid neoplasm (LBL)	953	000		11.1	1.3:1	13 (0-80)
LbcB         517         6.0         0.01         11         0.1-80           Habur B coll noplasms         6242         72.5         1.21         38 (040)           B- ordymphocytic fusionia         160         1.9         1.61         62 (31-43)           B- ordymphocytic fusionia         17         0.2         0.41         63 (62-78)           Fairy cell lexientia         8         0.1         1.7.1         48 (72-78)           Valid statution is macroglobulinemia         26         0.3         2.7.1         70 (48-48)           Multiple myeloma         26         0.3         2.7.1         70 (48-48)           Multiple myeloma         1311         15.2         1.3.1         61 (0-78)           Multiple myeloma         68         0.8         1.8.1         57 (70-49)           Extrancial marginal zone hymphoma         145         1.7         1.6.1         53 (4-66)           Felicinal tymptoma         247         2.9         0.9.1         52 (2-39)           Hig grade         247         2.9         0.3.1         52 (2-39)           Hig grade         247         2.9         0.3.1         52 (2-39)           Hig grade         247         2.9         0.3.1 <td>LBL, NUS</td> <td></td> <td>266</td> <td></td> <td>3.1</td> <td>1.3:1</td> <td>11 (0-78)</td>	LBL, NUS		266		3.1	1.3:1	11 (0-78)
Lab1         1/0         2.0         2.31         19 (1-80)           Chronic inpubsions         62/2         72         1.21         58 (0-94)           Chronic inpubsions         160         1.9         1.61         67 (21-33)           Splenci marginal zone lymptoma         5         0.1         4.1         65 (22-71)           Splenci marginal zone lymptoma         6         0.1         1.7.1         48 (27-66)           Lymptoplasmexyle lymptoma         26         0.3         2.7.1         70 (48-44)           Law grade B call lymptoma, unclassified         20         0.2         1.4.1         64 (16-78)           Valdenstrum secolobulinemia         131         1.5.2         1.3.1         61 (3-42)           Plasmexylorina         1451         1.6         0.8         1.8.1         57 (20-49)           Low grade         247         2.9         0.9.1         52 (23-91)           Low grade         1451         1.6         3.3.1         66 (3-42)           NOS         2         0         3.0         0         3.0         60 (40-76)           Nos         2         2.0         3.1         56 (4-9.4)         5         1.6         3.2.1         56 (4-9.4)	LBL-B		517		6.0	1.0:1	11 (0-79)
Nature         C/LD         C/LD <thc ld<="" th="">         C/LD         C/LD         <t< td=""><td>LBL-I</td><td>0040</td><td>170</td><td></td><td>2.0</td><td>2.3:1</td><td>19 (1-80)</td></t<></thc>	LBL-I	0040	170		2.0	2.3:1	19 (1-80)
Untrol         1.9         1.9         1.9         1.9         1.0         1.4         1.6         1.2         1.4         1.6         1.2         1.5         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.6         1.7         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.6         1.7         1.7         1.6         1.7         1.7         1.6         1.7         1.7         1.6         1.7         1.7         1.6         1.7<	Mature B cell neoplasms	6242	100		72.5	1.2:1	58 (0-94)
b-program         0         0.1         4.1         66 (22-79)           Hairy cell leukemia         8         0.1         1.7.1         42 (27-46)           Waldestrom's macroglobulinemia         26         0.3         2.7.1         70 (48-48)           Low grade B (hyphona, unclassified         20         0.2         1.4.1         66 (16-78)           Multiple myelona         1311         15.2         1.3.1         61 (30-42)           Paramosynna         68         0.8         1.8.1         57 (20-49)           Extrancial maginal zine lymphona         1451         1.6         8         9.1           Folloadi maginal zine lymphona         91         1.1         2.3.1         46 (10-24)           Folloadi maginal zine lymphona         91         1.1         2.3.1         46 (10-24)           Folloadi maginal zine lymphona         91         1.1         2.3.1         46 (10-24)           Folloadi maginal zine lymphona         145         1.7         1.6         3.3.1         46 (2-34)           Multic sell mynchona         145         1.7         1.6         3.4         46 (40-74)           Multic sell mynchona         126         2.20         2.3         1.3.1         56 (2-94)	Chronic lymphocytic leukernia		160		1.9	1.0:1	62 (31-93)
Spanie marginal Zule symptoma         F         C2         C4-11         C4 (27-46)           Lymphoplasmacytic lymphona         55         0.6         2.1:1         C6 (27-47)           Walderstorm's macroplobilemia         26         0.3         2.7:1         70 (48-44)           Low grade B cell lymphona, unclassified         20         0.2         1.4:1         64 (16-78)           Multiple mysiona         68         0.8         1.8:1         57 (20-49)           Extrancial marginal zone lymphoma         1451         16.8         0.9:1         54 (10-49)           Nodi marginal zone lymphoma         91         1.1         2.3:1         46 (12-44)           Fullicular lymphoma         397         4.9         1.15         52 (4-6)           Nodi         marginal zone lymphoma         146         1.7         1.6:1         53 (4-66)           Nodi         marginal zone lymphoma         12         0         2.0         38 (17-5)           Pinary cataneous FCL         3         0         3.0         66 (07-46)           Martie cell lymphoma         16         3.2:1         66 (97-46)           Diffase targe B cell lymphoma         16         3.3:1         66 (37-46)           Primary OtaS DLGC	B-protymphocytic tymphoma		5 17		0.1	4:1	63 (52-71)
har year bis         b         0.1         1.7.1         44 (2-40)           Wade instants         55         0.6         2.1.1         70 (48-44)           Low grads Bellymphona, unclassified         20         0.2         1.4.1         64 (16-73)           Multipe myeloma         1311         15.2         1.3.1         61 (30-92)           Pasmacytoma         68         0.8         1.8.1         57 (20-69)           Extranced marginal zone kymphoma         91         1.1         2.2.3         46 (12-49)           Follicular lymphoma         937         4.9         1.1.1         52 (23-91)           Hagt grade         145         1.7         1.6.1         35 (4-86)           NOS         2         0         2.0         38 (17-59)           Primary cataneous FQ.         3         0         3.0         60 (40-76)           DUBO, NOS         1879         2.3         1.3.1         58 (2-94)           Primary cataneous FQ.         236         2.5         3.1         58 (2-64)           Primary cataneous DUBO.         236         2.1         2.8 (4-74)         2.9 (12-62)           DUBO., NOS         1679         2.3         3.3.1         58 (2-64)      <	Spienic marginal zone lymphoma		17		0.2	0.4:1	04 (32-79)
Chronophasmalayae, mynunna         33         0.6         2.1.1         660 (2-7-7)           Wadderstorm's macropioulinemia         26         0.2         1.4.1         64 (16-78)           Multiple mynohoma, unclassified         20         0.2         1.4.1         64 (16-78)           Multiple mynohoma         1311         15.2         1.3.1         61 (30-92)           Plasmacytoma         68         0.8         1.8.1         57 (20-98)           Extrancel marginaliza one hynohoma         91         1.1         2.3.1         46 (12-94)           Low grade         247         2.9         0.9.1         52 (23-91)           Initige mynohoma         247         2.9         0.2         28 (17-97)           NOS         20         2.0         38 (17-59)         90 (13.1)         52 (23-91)           Primary chaneous FQL         3         0         3.0         66 (37-8)         68 (37-80)           Primary chaneous DLBCL         236         2.7         1.2.1         58 (19-49)           DLBCL, NOS         1879         2.3         1.3.1         58 (2-92)           DLBCL, NOS         1879         2.3         1.3.1         58 (2-92)           DLBCL, NOS         67         <	Hally cell leukellila		0		0.1	1.711	40 (27-00)
vicus soluti s in accognomenta         20         0.3         2.1.1         0.10 (900-99)           Low grade S coll imprhoma, unclassified         20         1.3.1         15.2         1.4.1         64 (16–78)           Multiple myeloma         1311         15.2         1.3.1         61 (0–99)           Extrancial analysinal zone lymphoma         1451         16.8         9.9.1         54 (10–99)           Nodal marginal zone lymphoma         397         4.9         1.1.1         52 (23–40)           Low grade         247         2.9         0.8.1         55 (23–91)           NoS         145         1.7         1.6.1         53 (4-96)           NoS         247         2.9         0.8.1         55 (23–91)           NoS         247         0         3.0         60 (40–76)           NoS         2.2         0         2.0         3.8         (17–59)           Primary cutaneous FUL         3         0         3.0         60 (40–76)           DLEGL, NOS         1879         2.1.3         1.3.1         68 (2–94)           Primary cutaneous DLBCL         235         2.2.1         1.86 (19–26)           Primary cutaneous DLBCL         67         0.8         0.6.1	Lymphopiasmacytic tymphoma Weldenetrom'e meeredebulinemie		22		0.0	2.1.1	00 (27-07) 70 (49 94)
Durg quarks D cent printprints, inclassing         D <thd< th=""> <thd< th="">         D         D</thd<></thd<>	Waldelistrolli s macrogrobulinemia		20		0.3	2.7.1	70 (40-04)
Integrinal ingenita         151         162         1.31         01 (30-32)           Extranctal marginal zone lymphoma         1451         16.8         0.91         54 (10-69)           Kotal marginal zone lymphoma         91         1.1         2.31         46 (12-84)           Fallicalar lymphoma         397         4.9         1.1.1         52 (4-91)           Low grade         247         2.9         0.9.11         52 (23-91)           Indegrade         145         1.7         1.61         53 (4-86)           NOS         2         0         2.0         38 (17-59)           Primary outaneous FGL         3         0         3.0         66 (37-66)           NOS         2235         2.5         1.3.1         58 (2-92)           DiBclo, NOS         1879         2.1.3         1.3.1         58 (2-62)           DiBclo, NOS         1879         2.1.2         1.8.1         58 (2-82)           Dimary outaneous DLBCL         6         0.1         2.1         58 (12-62)           Dimary outaneous DLBCL         6         0.2.1         1.8 (2-82)         1.8 (2-82)           Dimary outaneous DLBCL         6         0.1         2.1         58 (2-82)	Low grade 6 cell lymphoma, unclassified		20		0.2	1.4:1	04 (10-70) 61 (20, 02)
Pressnayolina         Oo         Io.1         J. (20–89)           Kotan marginal zone lymphoma         91         1.1         2.3.1         46 (12–46)           Nodal marginal zone lymphoma         91         1.1         2.3.1         46 (12–46)           Low grade         247         2.9         0.9.1         52 (23–91)           High grade         145         1.7         1.6.1         53 (4–86)           NOS         2         0         2.0         33 (7–56)           Primary cutaneous FCL         3         0         3.0         66 (7–76)           Martic cell lymphoma (UBCL)         2236         2.5.5         1.3.1         58 (2–94)           Primary CNS DLBCL         237         2.7         1.2.1         58 (16–74)           DHase targe B cell lymphoma         67         0.8         0.61         2.9           Primary cutaneous DLBCL         67         0.4         0.4         1.41         61 (32–83)           Primary mediastinal large B cell lymphoma         10         0.4         0.4         1.41         61 (32–83)           Lympositive DLBCJ, of defary         23         0.3         2.3.1         61 (32–83)           Lympositive DLBCJ, of defary         10         1.			60		13.2	1.0.1	67 (30-92)
Dubbal         Prioritical         Poil         Disb         Out-of         Out-of <thou-ou< th=""> <thou-ou< th="">         Out-of<td>FidSilidUjullid</td><td></td><td>1451</td><td></td><td>0.0</td><td>1.0.1</td><td>57 (20-09)</td></thou-ou<></thou-ou<>	FidSilidUjullid		1451		0.0	1.0.1	57 (20-09)
Notal magnia Lote griphona         91         1.1         2.3.1         46 (12–94)           Low grade         247         2.9         0.31         52 (23–91)           High grade         145         1.7         1.61         53 (4–86)           NOS         2         0         2.0         38 (17–59)           Primary cutaneous FCL         3         0         3.0         66 (40–76)           Mante cell kymphoma (DLBCL)         2236         2.5.5         1.3.1         58 (2–92)           Diffuse large B cell kymphoma (DLBCL)         2235         2.7         1.2.1         58 (19–83)           Primary cutaneous DLBCL         6         0.1         2.1         58 (19–83)           Primary cutaneous DLBCL         6         0.1         2.1         58 (19–83)           Primary mediastinal large B cell kymphoma         34         0.4         1.4.1         61 (32–83)           Primary mediastinal large B cell kymphoma         2         0.3         1.6 (3–63)         1.6 (2–83)           Primary mediastinal large B cell kymphoma         10         0.1         2.3 (3-76)         1.6 (2–83)           Primary mediastinal large B cell kymphoma         163         0.4         0.4 (14–71)         62 (19–80) <td< td=""><td>Nodel marginal zone lymphome</td><td></td><td>01</td><td></td><td>10.0</td><td>0.9.1</td><td>04 (10-09) 46 (10 04)</td></td<>	Nodel marginal zone lymphome		01		10.0	0.9.1	04 (10-09) 46 (10 04)
Follicatal minipulona         397         4-3         1.11         32 (4-91)           Low grafe         145         1.7         1.6.1         53 (4-86)           NOS         2         0         2.0         38 (17-59)           Primary cutaneous FQL         3         0         3.0         66 (40-76)           Mentle cell lymphoma         136         1.6         3.3.1         66 (37-86)           Dituse large B cell lymphoma (DLBCL)         236         2.5         1.3.1         58 (2-92)           DIBCA, NOS         1879         2.1.3         1.3.1         58 (2-94)           Primary cutaneous DLBCL         6         0.1         2.1         62 (46-74)           Primary mediatischal large B cell lymphoma         34         0.4         1.4.1         61 (32-83)           Intravascular large B cell lymphoma         4         0         0.3.1         63 (3-76)           ALK-positive large B cell lymphoma         10         0.1         2.3.1         62 (1-90)           Primary mediate DLBCL/ burkit lymphoma         13         0.3         2.3.1         51 (5-86)           Intermediate DLBCL/Burkit lymphoma         23         0.3         2.3.1         51 (5-86)           Intermediate DLBCL/Burkit lymphoma <td>Nodal marginal zone tymphoma</td> <td></td> <td>91</td> <td></td> <td>1.1</td> <td>2.3:1</td> <td>40 (12-04)</td>	Nodal marginal zone tymphoma		91		1.1	2.3:1	40 (12-04)
Ling grade         247         2.5         0.3.1         32 (2-91)           High grade         145         1.7         1.6.1         53 (4-86)           NOS         2         0         2.0         38 (17-59)           Primary cultaneous FCL         3         0         3.0         60 (40-76)           Mantle cell lymphoma (LBCL)         2236         25.5         1.3.1         58 (2-92)           DLBCL, NOS         1879         21.3         1.3.1         58 (2-92)           Primary CMS DLBCL         235         2.7         1.2.1         58 (19-83)           Primary CMS DLBCL         6         0.1         2.1         62 (46-74)           EV positive DLBCL of elderly         49         0.6         1.2.1         58 (2-83)           Primary cultaneous DLBCL         67         0.8         0.6.1         2.9 (12-62)           Intrasecular large B cell lymphoma         34         0.4         0.4.11         61 (32-83)           Lymphomatolig graulomatosis         4         0         0.3.1         63 (7-76)           ALK- positive large B cell lymphoma         2         0.0         1.1         77 (7-78)           Intermediate DLBCL/Burkitt lymphoma         23         0.3         2.3	Folicular lymphoma		397	047	4.9	1.1.1	52 (4-91)
Intermediate         Instruction         Instruction <thinstruction< th=""> <thinstruction< th=""></thinstruction<></thinstruction<>	Low grade			247	2.9	1.6.1	52 (23-91)
Primary cutaneous FCL         2         0         2.0         30         1(PT-39)           Mantle cell lymphoma         136         1.6         3.1         66 (37-86)           DLBGL, NCS         1879         21.3         1.3:1         58 (2-92)           Primary CMS DLBCL         235         2.7         1.2:1         58 (19-33)           Primary CMS DLBCL         235         2.7         1.2:1         58 (19-43)           Primary CMS DLBCL         6         0.1         2:1         62 (46-74)           EW positive DLBCL of elderly         49         0.6         1.2:1         58 (2-83)           Primary undiastinal targe B cell lymphoma         34         0         0.3:1         63 (3-76)           ALK-positive targe B cell lymphoma         10         0.1         2.3:1         62 (19-30)           Primary effusion lymphoma         2         0.0         1.1         77 (75-78)           Intermediate DLBCU/HL         18         0.2         0.8:1         28 (19-36)           Primary effusion lymphoma         1091         1.7         1.7:1         52 (1-90)           Aggressive NK cell leukemia         36         0.4         1.4:1         44 (14-81)           Systemic T-cell LPD of childhood <td></td> <td></td> <td></td> <td>140</td> <td>1.7</td> <td>2.0</td> <td>28 (17 50)</td>				140	1.7	2.0	28 (17 50)
Initialy dualations (CL         Image of the constraint of the constra	Primany cutanoous ECI			2	0	2.0	50 (17–59) 60 (40, 76)
Intermediate         100         1.3         3.3.1         60 (37-60)           DLBCL, NOS         1879         2.1.3         1.3.1         58 (2-92)           DLBCL, NOS         2355         2.7         1.2.1         58 (19-83)           Primary CNS DLBCL         6         0.1         2.1         62 (46-74)           EBV positive DLBCL of elderly         49         0.6         1.2.1         62 (46-74)           EBV positive DLBCL of elderly         49         0.4         1.4.1         61 (32-83)           Lymphomatoid granulomatosis         4         0         0.3.1         63 (3-76)           ALK-positive large B cell lymphoma         10         0.1         2.3.1         62 (21-90)           Primary mediuation lymphoma         10         0.1         2.3.1         61 (5-86)           Intermediate DLBCL/Burkit lymphoma         2         0.0         1:1         77 (75-78)           Intermediate DLBCL/Burkit lymphoma         163         1.9         2.9:1         35 (0-85)           Mature T and Kcell neoplasms         1091         11.7         1.7         1.7         1.2 (1-96)           Adutt T cell LPD of childhood         4         0         3:1         12 (7-47)           Hydro vacccinto	Mantle cell lymphoma		136	5	16	3.0 3.3·1	66 (37-86)
Bindse ange Deter imploring (ELDC)         22.0         18.71         50 (2-94)           Primary CNS DLBCL         235         2.7         1.2:1         58 (19-83)           Primary CNS DLBCL         6         0.1         2:1         58 (2-94)           Primary cutaneous DLBCL         6         0.1         2:1         58 (2-83)           Primary mediastinal large B cell lymphoma         67         0.8         0.6:1         29 (12-62)           Intravascular large B cell lymphoma         34         0.4         1.4:1         61 (32-83)           Lymphomatoid granulomatois         4         0         0.3:1         63 (7-70)           ALK-positive large B cell lymphoma         10         0.1         2.3:1         62 (21-90)           Primary effusion lymphoma         2         0.0         1:1         77 (75-78)           Intermediate DLBCL/Burkit lymphoma         163         1.9         2.9:1         35 (0-85)           Mature T and NK cell neuplasms         1091         11.7         1.7:1         52 (1-96)           Aggressive NK cell leukemia         36         0.4         1.4:1         44 (14-81)           Systemic T-cell LPD of childhood         4         0         3:1         12 (7-47)           Hymphoma<	Diffuse Jarge B cell lymphoma (DLBCL)		2236		25.5	1 2.1	58 (2-02)
Diabata, Rod       103       21.3       1.5.1       50 (2-94)         Primary CUS DLBCL       235       2.7       1.2.11       68 (19-83)         Primary cutaneous DLBCL       6       0.1       2.11       68 (19-83)         Primary mediastinal large B cell lymphoma       67       0.8       0.61       29 (12-62)         Intravascular large B cell lymphoma       34       0.4       1.4:1       61 (32-83)         Lymphomatoid granulomatosis       4       0       0.3:1       63 (3-76)         ALK-positive large B cell lymphoma       10       0.1       2.3:1       62 (19-36)         Plasmablastic lymphoma       10       0.1       2.3:1       62 (19-36)         Intermediate DLBCL/Burkitt lymphoma       23       0.3       2.3:1       51 (5-86)         Intermediate DLBCL/Burkitt lymphoma       163       19       2.9:1       35 (0-85)         Mature T and NK cell neoplasms       1091       11.7       1.7:1       52 (1-96)         Aggressive NK cell leukemia       36       0.4       1.4:1       44 (14-81)         Systemic T-cell LPD of childhood       4       0       3:1       12 (7-47)         Hydroa vasciniforme-like lymphoma       26       0.3       1.6:1       5			2250	1870	20.0	1.3.1	58 (2-92)
Primary outlaneous DLBCL       6       1.2.1       62 (13 - 63)         Primary cutaneous DLBCL       6       1.2.1       62 (46 - 74)         EV positive DLBCL of elderly       49       0.6       1.2.1       52 (46 - 74)         EV positive DLBCL of elderly       49       0.6       1.2.1       52 (46 - 74)         Intravascular large B cell lymphoma       34       0.4       1.4.1       61 (32 - 83)         Lymphomatoid granulomatosis       4       0       0.3.1       63 (3 - 76)         ALK-positive large B cell lymphoma       10       0.1       2.3.1       62 (19 - 30)         Plasmablastic lymphoma       10       0.1       2.3.1       62 (19 - 30)         Plasmablastic lymphoma       2       0.0       1:1       77 (75 - 78)         Intermediate DLBCL/HL       18       0.2       0.8:1       28 (19 - 83)         Burkitt lymphoma       163       1.9       2.9:1       35 (0 - 85)         Mature T and NK cell neoplasms       1091       11.7       1.7.1       52 (1 - 90)         Agterssive NK cell leukemia       36       0.4       1.4:1       44 (14 - 81)         Systemic T-cell LPD of childhood       4       0       3:1       12 (7 - 47)         Hyd	Primary CNS DI BCI			235	21.5	1.0.1	58 (19-83)
Initial Control       Constraints       Constraints <thconstraints< t<="" td=""><td>Primary cutaneous DI BCI</td><td></td><td></td><td>6</td><td>0.1</td><td>2.1</td><td>62 (46-74)</td></thconstraints<>	Primary cutaneous DI BCI			6	0.1	2.1	62 (46-74)
Drind point       10       121       05       121       05       121       05       121       05       121       05       121       05       121       05       121       05       121       05       05       121       05       05       121       05       05       121       05       05       121       05       05       121       05	FRV positive DI BCL of elderly			49	0.1	1 2.1	58 (2-83)
Thinkay inductance         Diamage         Diamage <thdiamage< th="">         Diamage         <thdiamage< th="">         Diamage         <thdiamage< th=""></thdiamage<></thdiamage<></thdiamage<>	Primary mediastinal large B cell lymphoma			67	0.8	0.6.1	29 (12-62)
Lymphomatosis       4       0       0.1       11.1       01 (0.20)         ALK-positive large B cell lymphoma       10       0.1       2.3.1       62 (21-90)         Primary effusion lymphoma       10       0.1       2.3.1       62 (21-90)         Primary effusion lymphoma       2       0.0       1.1       77 (75-78)         Intermediate DLBCL/Eurkitt lymphoma       23       0.3       2.3.1       51 (5-86)         Intermediate DLBCL/HL       18       0.2       0.8:1       28 (19-83)         Burkitt lymphoma       163       1.9       2.9:1       35 (0-85)         Mature T and NK cell neoplasms       1091       11.7       1.7:1       52 (1-96)         Aggressive NK cell leukemia       36       0.4       1.4:1       44 (14-81)         Systemic T-cell LPD of childhood       4       0       3:1       12 (7-47)         Hydra vasciniforme-like hymphoma       5       0.1       0.3:1       49 (28-58)         Extranodal NVT cell lymphoma       13       0.2       1.6:1       54 (21-74)         Hydraspacited T cell lymphoma       13       0.2       1.6:1       54 (21-74)         Hydraspacited T cell lymphoma       13       0.2       1.6:1       14 (19-73) <td>Intravascular large B cell lymphoma</td> <td></td> <td>34</td> <td>07</td> <td>0.0</td> <td>1 4.1</td> <td>61 (32-83)</td>	Intravascular large B cell lymphoma		34	07	0.0	1 4.1	61 (32-83)
Alk-positive large B cell lymphoma       4       0       4:0       28 (19–36)         Plasmablastic lymphoma       10       0.1       2.3:1       62 (21–90)         Primary effusion lymphoma       2       0.0       1:1       77 (75–78)         Intermediate DLBCL/Burkitt lymphoma       23       0.3       2.3:1       51 (5–86)         Intermediate DLBCL/Burkitt lymphoma       163       1.9       2.9:1       35 (0–85)         Mature T and NK cell neoplasms       1091       11.7       1.7:1       52 (1–96)         Aggressive K cell leukemia       36       0.4       1.4:1       44 (14-81)         Systemic T-cell LPD of childhood       4       0       3:1       12 (7–47)         Hydrav vacciniforme-like lymphoma       5       0.1       0.3:1       12 (7–47)         Hydrav ascciniforme-like lymphoma       2       0       0/22       13 (8–18)         Adult T cell leukemia/lymphoma       5       0.1       0.3:1       42 (21–74)         Hydravascciniforme-like lymphoma       13       0.2       1.6:1       54 (21–74)         Hydravascciated T cell lymphoma       13       0.2       1.6:1       41 (19–73)         Subcutaneous panniculitis-like TCL       24       0.3       0.3:	Lymphomatoid granulomatosis		4		0.4	0.3.1	63 (3-76)
Plasmabilastic lymphoma       10       1.3       1.6       1.6       1.6       1.6       1.6       1.6       1.6       1.6       1.7       1.7       1.7       1.7       1.7       1.7       7.7       7.5–78       1.8       1.6       1.6       1.6       1.6       1.6       1.6       1.6       1.7       7.7       7.5–78       1.8       1.6       1.7       1.7       1.7       1.7       1.7       1.5       1.6       8.6       0.8       1.9       2.9:1       35       0.6–85       3.5       0.1       0.2       0.8:1       2.8       (19–83)         Burkit Hymphoma       163       1.9       2.9:1       35       (0–85)       35       (0–85)       3.5       (0–85)       (1–96)       4.4       (14–81)       3.5       (1–96)       4.4       (14–81)       3.5       (1–96)       4.4       (14–81)       3.5       (1–74)       1.7       1.7:1       52       (1–90)       3.6       (18–30)       3.1       12       (2–47)       1.6       1.6       1.1       1.4       (14–81)       3.6       1.6       1.6       1.1       1.7       1.7:1       52       (6–91)       1.6       1.6       1.6       1.6 <t< td=""><td>Al K-positive Jarge B cell lymphoma</td><td></td><td>4</td><td></td><td>0</td><td>4.0</td><td>28 (19–36)</td></t<>	Al K-positive Jarge B cell lymphoma		4		0	4.0	28 (19–36)
Primary effusion lymphoma       10       0.1       1.1       775–78)         Intermediate DLBCL/Burkitt lymphoma       23       0.3       2.3:1       51 (5–86)         Intermediate DLBCL/HL       18       0.2       0.8:1       28 (19–83)         Burkitt lymphoma       163       1.9       2.9:1       35 (0–85)         Mature T and NK cell neoplasms       1091       11.7       1.7:1       52 (1–96)         Aggressive NK cell leukemia       36       0.4       1.4:1       44 (14–81)         Systemic T-cell LPD of childhood       4       0       3:1       12 (7–47)         Hydroa vacciniforme-like lymphoma       2       0       0:2       13 (8–18)         Adutt T cell leukemia/nymphoma       5       0.1       0.3:1       49 (28–58)         Extranodal NK/T cell lymphoma       26       0.3       1.6:1       54 (21–74)         Hepatosplenic T cell lymphoma       13       0.2       1.6:1       44 (19–73)         Subcutaneous pannicultis-like TCL       24       0.3       0.3:1       28 (14–56)         Mycosis fungoides       49       0.6       1.1:1       44 (3–88)         Primary cutaneous D30+ LPD       49       0.6       1.1:1       44 (3–88)	Plasmablastic lymphoma		10		0 1	2 3.1	62 (21-90)
Intermediate DLBCL/Burkitt lymphoma       23       0.3       2.3:1       51 (5-86)         Intermediate DLBCL/HL       18       0.2       0.8:1       28 (19-83)         Burkitt lymphoma       163       1.9       2.9:1       35 (0-85)         Mature T and NK cell neoplasms       1091       11.7       1.7:1       52 (1-96)         Aggressive NK cell leukemia       36       0.4       1.4:1       44 (14-81)         Systemic T-cell LPD of childhood       4       0       3:1       12 (7-47)         Hydroa vacciniforme-like lymphoma       2       0       0:2       13 (8-18)         Adult T cell leukemia/lymphoma       5       0.1       0.3:1       49 (28-58)         Extranodal NK/T cell lymphoma, nasal-type       365       4.2       1.9:1       52 (8-91)         Enteropathy-associated T cell lymphoma       26       0.3       1.6:1       54 (21-74)         Hepatosplenic T cell lymphoma       13       0.2       1.6:1       41 (19-73)         Subcutaneous panniculitis-like TCL       24       0.3       0.3:1       28 (14-56)         Mycosis fungoides       49       0.6       1.1:1       44 (15-74)         Primary cutaneous CD30+ LPD       49       0.6       1.5 <t< td=""><td>Primary effusion lymphoma</td><td></td><td>2</td><td></td><td>0.1</td><td>1.1</td><td>77 (75–78)</td></t<>	Primary effusion lymphoma		2		0.1	1.1	77 (75–78)
Intermediate DLBC/HL       18       0.2       0.8:1       28 (19–83)         Burkitt lymphoma       163       1.9       2.9:1       35 (0–85)         Mature T and Nk cell neoplasms       1091       11.7       1.7:1       52 (1–96)         Aggressive NK cell leukemia       36       0.4       1.4:1       44 (14–81)         Systemic T-cell LPD of childhood       4       0       3:1       12 (7–47)         Hydroa vacciniforme-like lymphoma       2       0       0:2       13 (8–18)         Adult T cell leukemia/lymphoma       26       0.3       1.6:1       54 (21–74)         Hepatosplenic T cell lymphoma, nasal-type       365       4.2       1.9:1       52 (8–91)         Enteropathy-associated T cell lymphoma       26       0.3       1.6:1       54 (21–74)         Hepatosplenic T cell lymphoma       13       0.2       1.6:1       41 (19–73)         Subcutaneous paniculitis-like TCL       24       0.3       0.3:1       28 (14–56)         Mycosis fungoides       49       0.6       1.1:1       44 (15–74)         Primary cutaneous PTCL       27       0.3       0.9:1       52 (21–91)         Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1	Intermediate DI BCI /Burkitt lymphoma		23		0.0	2.3.1	51 (5-86)
International barlies         163         1.2         0.5.1         1.20 (10 oc)           Burkit lymphoma         163         1.9         2.9.1         35 (2 - 96)           Aggressive NK cell leukemia         36         0.4         1.4:1         44 (14-81)           Systemic T-cell LPD of childhood         4         0         3:1         12 (7-47)           Hydroa vacciniforme-like lymphoma         2         0         0:2         13 (8-18)           Adult T cell leukemia/lymphoma         5         0.1         0.3:1         49 (28-58)           Extranodal NK/T cell lymphoma, nasal-type         365         4.2         1.9:1         52 (8-91)           Enteropathy-associated T cell lymphoma         26         0.3         1.6:1         54 (21-74)           Hepatosplenic T cell lymphoma         13         0.2         1.6:1         41 (19-73)           Subcutaneous pannicultits-like TCL         24         0.3         0.3:1         28 (14-56)           Mycosis fungoides         49         0.6         1:1         44 (3-8)           Primary cutaneous CD30+ LPD         27         0.3         0.9:1         52 (21-91)           Anaplastic large cell lymphoma (ALCL)         126         1.5         2:1         32 (1-81)	Intermediate DI BCI /HI		18		0.0	0.8.1	28 (19-83)
Mature T and NK cell neoplasms       1091       11.7       1.7       1.7       52 (1-96)         Aggressive NK cell leukemia       36       0.4       1.4:1       44 (14-81)         Systemic T-cell LPD of childhood       4       0       3:1       12 (7-47)         Hydroa vacciniforme-like lymphoma       2       0       0:2       13 (8-18)         Adult T cell leukemia/lymphoma       5       0.1       0.3:1       49 (28-58)         Extranodal NK/ cell lymphoma, nasal-type       365       4.2       1.9:1       52 (8-91)         Enteropathy-associated T cell lymphoma       26       0.3       1.6:1       41 (19-73)         Subcutaneous pannicultis-like TCL       24       0.3       0.3:1       28 (14-56)         Mycosis fungoides       49       0.6       1.1:1       44 (3-88)         Primary cutaneous CD30+ LPD       49       0.6       1:1       44 (3-88)         Primary cutaneous PTCL       27       0.3       0.9:1       52 (21-91)         Anglosimmunoblastic T cell lymphoma       147       1.7       1.9:1       64 (22-88)         Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1-81)         ALCL, ALK+       65       0.5       2:1	Burkitt lymphoma		163		19	2 9.1	35 (0-85)
Aggressive NK cell leukemia360.41.4:144 (1-61)Systemic T-cell LPD of childhood403:112 (7-47)Hydroa vacciniforme-like lymphoma200:213 (8-18)Adult T cell leukemia/lymphoma50.10.3:149 (28-58)Extranodal NK/T cell lymphoma, nasal-type3654.21.9:152 (8-91)Enteropathy-associated T cell lymphoma260.31.6:154 (21-74)Hepatosplenic T cell lymphoma130.21.6:141 (19-73)Subcutaneous panniculitis-like TCL240.30.3:128 (14-56)Mycosis fungoides490.61.1:144 (3-88)Primary cutaneous CD30+ LPD490.61.1:144 (3-88)Primary cutaneous PTCL270.30.9:152 (21-91)Angioimmunoblastic T cell lymphoma1471.71.9:164 (22-88)Anaplastic large cell lymphoma (ALCL)1261.52:132 (1-81)ALCL, ALK+650.82.1:121 (1-80)ALCL, ALK-450.52:158 (9-81)ALCL, NOS160.21.7:131 (6-69)Peripheral T cell lymphoma, NOS2182.51.9:156 (2-96)	Mature T and NK cell neonlasms	1091	100		11.7	1.7.1	52 (1-96)
Systemic T-cell LPD of childhood       4       0       3:1       12 (7-47)         Hydroa vacciniforme-like lymphoma       2       0       0:2       13 (8-18)         Adult T cell leukemia/lymphoma       5       0.1       0.3:1       49 (28-58)         Extranodal NK/T cell lymphoma, nasal-type       365       4.2       1.9:1       52 (8-91)         Enteropathy-associated T cell lymphoma       26       0.3       1.6:1       54 (21-74)         Hepatosplenic T cell lymphoma       13       0.2       1.6:1       41 (19-73)         Subcutaneous panniculitis-like TCL       24       0.3       0.3:1       28 (14-56)         Mycosis fungoides       49       0.6       1.1:1       44 (15-74)         Primary cutaneous CD30+ LPD       49       0.6       1.1:1       44 (15-74)         Primary cutaneous PTCL       27       0.3       0.9:1       52 (21-91)         Angioimmunoblastic T cell lymphoma       147       1.7       1.9:1       64 (22-88)         Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1-81)         ALCL, ALK+       65       0.8       2:1:1       21 (1-80)         ALCL, ALK+       45       0.5       2:1       58 (9-81)	Aggressive NK cell leukemia	1001	36		0.4	1 4.1	44 (14-81)
Hydroa vacciniforme-like lymphoma       2       0       0:2       13 (8–18)         Adult T cell leukemia/lymphoma       5       0.1       0.3:1       49 (28–58)         Extranodal NK/T cell lymphoma, nasal-type       365       4.2       1.9:1       52 (8–91)         Enteropathy-associated T cell lymphoma       26       0.3       1.6:1       54 (21–74)         Hepatosplenic T cell lymphoma       13       0.2       1.6:1       41 (19–73)         Subcutaneous panniculitis-like TCL       24       0.3       0.3:1       28 (14–56)         Mycosis fungoides       49       0.6       1.1:1       44 (3–88)         Primary cutaneous CD30+ LPD       49       0.6       1.1:1       44 (3–88)         Primary cutaneous CD30+ LPD       27       0.3       0.9:1       52 (21–91)         Angioimmunoblastic T cell lymphoma       147       1.7       1.9:1       64 (22–88)         Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1–81)         ALCL, ALK+       65       0.8       2:1:1       21 (1–80)         ALCL, NOS       16       0.2       1.7:1       31 (6–69)         Peripheral T cell lymphoma, NOS       218       2.5       1.9:1       56 (2–96	Systemic T-cell I PD of childhood		4		0	3:1	12 (7-47)
Adult T cell leukemia/lymphoma       5       0.1       0.3       49 (28-58)         Extranodal NK/T cell lymphoma, nasal-type       365       4.2       1.9:1       52 (8-91)         Enteropathy-associated T cell lymphoma       26       0.3       1.6:1       54 (21-74)         Hepatosplenic T cell lymphoma       13       0.2       1.6:1       44 (19-73)         Subcutaneous panniculitis-like TCL       24       0.3       0.3:1       28 (14-56)         Mycosis fungoides       49       0.6       1.1:1       44 (15-74)         Primary cutaneous CD30+ LPD       49       0.6       1.1:1       44 (3-88)         Primary cutaneous PTCL       27       0.3       0.9:1       52 (21-91)         Anaglastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1-81)         ALCL, ALK+       65       0.8       2.1:1       21 (1-80)         ALCL, ALK+       45       0.5       2:1       58 (9-81)         ALCL, NOS       16       0.2       1.7:1       31 (6-69)         Peripheral T cell lymphoma, NOS       218       2.5       1.9:1       56 (2-96)	Hydroa vacciniforme-like lymphoma		2		0	0:2	13 (8–18)
Extranodal NK/T cell lymphoma, nasal-type       365       4.2       1.9:1       52 (8–91)         Enteropathy-associated T cell lymphoma       26       0.3       1.6:1       54 (21–74)         Hepatosplenic T cell lymphoma       13       0.2       1.6:1       44 (21–74)         Hepatosplenic T cell lymphoma       13       0.2       1.6:1       44 (19–73)         Subcutaneous paniculitis-like TCL       24       0.3       0.3:1       28 (14–56)         Mycosis fungoides       49       0.6       1.1:1       44 (3–88)         Primary cutaneous CD30+ LPD       49       0.6       1.1       44 (3–88)         Primary cutaneous PTCL       27       0.3       0.9:1       52 (21–91)         Angioimmunoblastic T cell lymphoma       147       1.7       1.9:1       64 (22–88)         Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1–81)         ALCL, ALK+       65       0.8       2.1:1       21 (1–80)         ALCL, NOS       16       0.2       1.7:1       31 (6–69)         Peripheral T cell lymphoma, NOS       218       2.5       1.9:1       56 (2–96)	Adult T cell leukemia/lymphoma		5		0.1	0.3:1	49 (28–58)
Enteropathy-associated T cell lymphoma       26       0.3       1.6:1       54 (21–74)         Hepatosplenic T cell lymphoma       13       0.2       1.6:1       41 (19–73)         Subcutaneous paniculitis-like TCL       24       0.3       0.3:1       28 (14–56)         Mycosis fungoides       49       0.6       1.1:1       44 (15–74)         Primary cutaneous CD30+ LPD       49       0.6       1.1:1       44 (3–88)         Primary cutaneous PTCL       27       0.3       0.9:1       52 (21–91)         Angioimmunoblastic T cell lymphoma       147       1.7       1.9:1       64 (22–88)         Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1–81)         ALCL, ALK+       65       0.8       2.1:1       21 (1–80)         ALCL, NOS       16       0.2       1.7:1       31 (6–69)         Peripheral T cell lymphoma, NOS       218       2.5       1.9:1       56 (2–96)	Extranodal NK/T cell lymphoma, nasal-type		365		4.2	1.9:1	52 (8-91)
Hepatosplenic T cell lymphoma       13       0.2       1.6:1       41 (19–73)         Subcutaneous panniculitis-like TCL       24       0.3       0.3:1       28 (14–56)         Mycosis fungoides       49       0.6       1.1:1       44 (15–74)         Primary cutaneous CD30+ LPD       49       0.6       1.1       44 (3–88)         Primary cutaneous PTCL       27       0.3       0.9:1       52 (21–91)         Angioimmunoblastic T cell lymphoma       147       1.7       1.9:1       64 (22–88)         Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1–81)         ALCL, ALK+       65       0.8       2.1:1       21 (1–80)         ALCL, NOS       16       0.2       1.7:1       31 (6–69)         Peripheral T cell lymphoma, NOS       218       2.5       1.9:1       56 (2–96)	Enteropathy-associated T cell lymphoma		26		0.3	1.6:1	54 (21-74)
Subcutaneous paniculitis-like TCL       24       0.3       0.3:1       28 (14–56)         Mycosis fungoides       49       0.6       1.1:1       44 (15–74)         Primary cutaneous CD30+ LPD       49       0.6       1.1       44 (3–88)         Primary cutaneous PTCL       27       0.3       0.9:1       52 (21–91)         Angioimmunoblastic T cell lymphoma       147       1.7       1.9:1       64 (22–88)         Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1–81)         ALCL, ALK+       65       0.8       2.1:1       21 (1–80)         ALCL, NOS       16       0.2       1.7:1       31 (6–69)         Peripheral T cell lymphoma, NOS       218       2.5       1.9:1       56 (2–96)	Hepatosplenic T cell lymphoma		13		0.2	1.6:1	41 (19–73)
Mycosis fungoides       49       0.6       1.1:1       44 (15–74)         Primary cutaneous CD30+ LPD       49       0.6       1.1       44 (3–88)         Primary cutaneous PTCL       27       0.3       0.9:1       52 (21–91)         Angioimmunoblastic T cell lymphoma       147       1.7       1.9:1       64 (22–88)         Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1–81)         ALCL, ALK+       65       0.8       2.1:1       21 (1–80)         ALCL, NOS       16       0.2       1.7:1       31 (6–69)         Peripheral T cell lymphoma, NOS       218       2.5       1.9:1       56 (2–96)	Subcutaneous panniculitis-like TCL		24		0.3	0.3:1	28 (14–56)
Primary cutaneous CD30+ LPD         49         0.6         1:1         44 (3-88)           Primary cutaneous PTCL         27         0.3         0.9:1         52 (21-91)           Angioimmunoblastic T cell lymphoma         147         1.7         1.9:1         64 (22-88)           Anaplastic large cell lymphoma (ALCL)         126         1.5         2:1         32 (1-81)           ALCL, ALK+         65         0.8         2.1:1         21 (1-80)           ALCL, NLK-         45         0.5         2:1         58 (9-81)           ALCL, NOS         16         0.2         1.7:1         31 (6-69)           Peripheral T cell lymphoma, NOS         218         2.5         1.9:1         56 (2-96)	Mycosis fungoides		49		0.6	1.1:1	44 (15–74)
Primary cutaneous PTCL         27         0.3         0.9:1         52 (21–91)           Angioimmunoblastic T cell lymphoma         147         1.7         1.9:1         64 (22–88)           Anaplastic large cell lymphoma (ALCL)         126         1.5         2:1         32 (1–81)           ALCL, ALK+         65         0.8         2.1:1         21 (1–80)           ALCL, ALK-         45         0.5         2:1         58 (9–81)           ALCL, NOS         16         0.2         1.7:1         31 (6–69)           Peripheral T cell lymphoma, NOS         218         2.5         1.9:1         56 (2–96)	Primary cutaneous CD30+ LPD		49		0.6	1:1	44 (3-88)
Angloimmunoblastic T cell lymphoma       147       1.7       1.9:1       64 (22–88)         Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1–81)         ALCL, ALK+       65       0.8       2.1:1       21 (1–80)         ALCL, ALK-       45       0.5       2:1       58 (9–81)         ALCL, NOS       16       0.2       1.7:1       31 (6–69)         Peripheral T cell lymphoma, NOS       218       2.5       1.9:1       56 (2–96)	Primary cutaneous PTCL		27		0.3	0.9:1	52 (21-91)
Anaplastic large cell lymphoma (ALCL)       126       1.5       2:1       32 (1-81)         ALCL, ALK+       65       0.8       2.1:1       21 (1-80)         ALCL, ALK-       45       0.5       2:1       58 (9-81)         ALCL, NOS       16       0.2       1.7:1       31 (6-69)         Peripheral T cell lymphoma, NOS       218       2.5       1.9:1       56 (2-96)	Angioimmunoblastic T cell lymphoma		147		1.7	1.9:1	64 (22–88)
ALCL, ALK+     65     0.8     2.1:1     21 (1-80)       ALCL, ALK-     45     0.5     2:1     58 (9-81)       ALCL, NOS     16     0.2     1.7:1     31 (6-69)       Peripheral T cell lymphoma, NOS     218     2.5     1.9:1     56 (2-96)	Anaplastic large cell lymphoma (ALCL)		126		1.5	2:1	32 (1-81)
ALCL, ALK-     45     0.5     2:1     58 (9–81)       ALCL, NOS     16     0.2     1.7:1     31 (6–69)       Peripheral T cell lymphoma, NOS     218     2.5     1.9:1     56 (2–96)	ALCL, ALK+		0	65	0.8	2.1:1	21 (1-80)
ALCL, NOS         16         0.2         1.7:1         31 (6–69)           Peripheral T cell lymphoma, NOS         218         2.5         1.9:1         56 (2–96)	ALCL, ALK-			45	0.5	2:1	58 (9–81)
Peripheral T cell lymphoma, NOS 218 2.5 1.9:1 56 (2–96)	ALCL, NOS			16	0.2	1.7:1	31 (6–69)
	Peripheral T cell lymphoma, NOS		218		2.5	1.9:1	56 (2–96)

ALCL=anaplastic large cell lymphoma, ALK=anaplastic lymphoma kinase, CNS=central nervous system, DLBCL=diffuse large B cell lymphomas, EBV=Epstein-Barr virus, FCL=follicle center lymphoma, HL=Hodgkin lymphoma, LBL=lymphoblastic leukemia, LP=lymphocyte predominant, LPD=lymphoproliferative disease, TCL=T cell lymphoma.



Figure 1. Distribution of histologic subtypes of 8615 patients with lymphoid neoplasm diagnosed between 1997 and 2016. CLL=chronic lymphocytic leukemia/ small lymphocytic lymphoma, extranodal MZL=extranodal marginal zone lymphoma of mucosal-associated lymphoid tissue, MZL=marginal zone lymphoma, PTCL, NOS=peripheral T cell lymphoma, not otherwise specified, TCL=T cell lymphoma.

most common subtype, accounting for 4.2% (365 cases) of all lymphoid neoplasms, followed by peripheral T cell lymphoma, not otherwise specified (PTCL, NOS) (218 cases, 2.5%), angioimmunoblastic T cell lymphoma (147 cases, 1.7%), and anaplastic large cell lymphoma (126 cases, 1.5%) (Table 1; Fig. 1).

## 3.3. Subtype distribution according to age and gender

Most lymphoid neoplasm subtypes were male predominant, except for splenic marginal zone lymphoma (MZL) (M:F= 0.4:1), ENMZL (M:F=0.9:1), primary mediastinal large B cell lymphoma (M:F=0.6:1), subcutaneous panniculitis-like T cell lymphoma (M:F=0.3:1), and primary cutaneous T cell lymphoma, NOS (M:F=0.9:1). Median patient age was 32 years (range: 6-92) in Hodgkin lymphoma, 15 years (range: 0-80) in lymphoblastic neoplasms, 58 years (range: 0-94) in mature B cell neoplasms, and 52 years (range: 1-96) in mature T cell neoplasms (Table 1).

According to age grouping, the most frequent subtype was lymphoblastic neoplasms in the first and second decades and diffuse large B cell lymphoma and Hodgkin lymphoma in the third decade. Subsequently, diffuse large B cell lymphoma was the most frequent subtype among adults and older adults. Extranodal marginal zone lymphoma was the second most frequent subtype among those in their 40s, 50s, and 60s, while among those in their 70s to 90s, plasma cell neoplasms were the second most common subtype (Supplementary Table 2, http://links.lww. com/MD/D318). Distribution of predominant subtype differed based on gender. Burkitt lymphoma is more prevalent among boys, so in the first decade, male Burkitt lymphoma was the second most common lymphoma, followed by lymphoblastic leukemia/lymphoma (but not in girls). Likewise, ENMZL showed a slight female predominance; thus, in their 40s and 50s, ENMZL was the most frequent subtype among female patients (but not males) (Supplementary Tables 3 and 4, http:// links.lww.com/MD/D318).

#### 3.4. Subtype distribution according to biopsy site

Subtype distribution differed according to site. In lymph nodes, the most frequent subtypes (in descending frequency) were diffuse large B cell lymphoma (n=588, 33.1%), follicular lymphoma (n=268, 15.1%), and Hodgkin lymphoma (n=243, 13.7%). In bone marrow, plasma cell myeloma was the most common subtype, accounting for 48.2% of 2233 cases, followed by lymphoblastic neoplasms, accounting for 34.9%. In the extranodal sites, diffuse large B cell lymphoma (n=1586, 35.8%) and ENMZL (n=1437, 32.5%) were the predominant subtypes, followed by extranodal NK/T cell lymphoma (n=350, 7.9%), plasma cell neoplasm (n=145, 3.3%), follicular lymphoma (n= 126, 2.8%), and PTCL, NOS (n=102, 2.3%). In the stomach, ENMZL (n=891, 72.5%) and diffuse large B cell lymphoma (n= 269, 21.9%) were the major subtypes. Diffuse large B cell

lymphoma (n=50, 31.6%), lymphoblastic lymphoma (n=48, 30.4%), and Hodgkin lymphoma (n=39, 24.7%) were prominent subtypes in the mediastinum. In the eye, ENMZL accounted for 89.6% of 280 cases. In the nasal cavity, extranodal NK/T cell lymphoma (n=221, 75.7%), diffuse large B cell lymphoma (n= 36, 12.3%), and plasma cell neoplasm (n=17, 5.8%) were the most common subtypes (Supplementary Table 1, http://links. lww.com/MD/D318).

# 3.5. Changing trends in the relative frequency of subtypes among lymphoid neoplasms

3.5.1. Change in the number of patients with lymphoid neoplasms. We evaluated changes in the number of patients and relative frequency of lymphoma subtypes over two decades (Table 2). The number of patients who have visited the Samsung Medical Center since 1997 has continued to increase. In 1997-2006, the number of patients with lymphoid neoplasm was 3024, and 5591 in 2007-2016, that is, an average increase of 1.85 times over the 20-year study period. Increased rates were higher in Hodgkin lymphoma (2.16 times) and mature B cell lymphoma (2.03 times), but changes in rates of precursor lymphoid neoplasms and mature T cell lymphoma did not reach the average increase (1.41 and 1.36 times, respectively). Among B cell lymphomas, remarkably, the increase in CLL/SLL, plasma cell neoplasms, follicular lymphoma, and mantle cell lymphoma, especially follicular lymphoma more than doubled, exceeding the average rate of increase, while increase in Burkitt lymphoma was minimal (1.2 times). ENMZL showed the average rate of increase. Among mature T cell lymphomas, the number of patients with angioimmunoblastic T cell lymphoma increased 2.27 times; however, among those with other types of T cell lymphomas, the rate of increase was lower than average.

**3.5.2.** Change in the proportion of subtypes among all *lymphoid neoplasms.* To evaluate changes in the proportion of subtypes, crude rate of each subtype per 100 lymphoma patients during each decade and age adjusted rate were calculated. Crude

rate and age adjusted rate were increased in Hodgkin's lymphoma and mature B cell lymphoma while precursor lymphoid neoplasms and mature T cell lymphoma were decreased (Table 2).

Among B cell neoplasms, age adjusted rate of plasma cell neoplasm, follicular lymphoma, mantle cell lymphoma increased while there was no significant change in extranodal marginal zone lymphoma and Burkitt lymphoma. The increase in lowgrade follicular lymphoma was ascribed to an increase in both nodal follicular lymphoma of low grade and to duodenal-type follicular lymphoma (data not shown). Among mature T and NK cell lymphomas, the proportions of subtypes decreased, except for angioimmunoblastic T cell lymphoma.

3.5.3. Comparisons with national data. Total numbers and proportions of major lymphoid neoplasm subtypes in our hospital were compared with data from previously published nationwide studies, initiated by the Hematolymphoid Study Group of the Korean Society of Pathologists (KSP) and the Korean National Cancer Incidence Database (KNCIDB) based on the national population-based cancer-registry program initiated by the Korean Ministry of Health and Welfare. As shown in Table 3, each dataset has confounds. KSP data include very low number of plasma cell neoplasms and precursor cell neoplasms, which are mainly diagnosed in bone marrow. KNCIDB data contain a high number of undetermined type of lymphoid neoplasms in which immunophenotype information is insufficient for diagnosis according to the WHO classification. Compared with the KNCIDB data, rates from our hospital are similar for precursor cell neoplasms, plasma cell neoplasms, and mature T/NK cell neoplasms, while rates of ENMZL and follicular lymphoma are higher. Compared with KSP data, the proportion of T/NK cell neoplasm at our hospital was significantly lower.

**3.5.4.** Comparison with data from other countries. Comparing our data for 2007–2016 with those from Japan and China for

## Table 2

	Changes	of major	subtype	distribution	of lymphoid	neoplasms	over past	20 years
--	---------	----------	---------	--------------	-------------	-----------	-----------	----------

		1997-2006		2007–2016			
Diagnosis	No. of patients	Proportion (%) of subtype	Age adjusted rate	No. of patients	Proportion (%) of subtype	Age adjusted rate	
Total cases	3024			5591			
Hodgkin lymphoma	104	3.4	0.2	225	4	0.3	
Precursor lymphoid neoplasms	396	13.1	0.9	557	10	0.7	
Mature B-cell neoplasms	2062	68.2	3.2	4180	74.8	3.5	
Chronic lymphocytic leukemia	51	1.7	0.1	109	1.9	0.1	
Plasma cell neoplasms	426	14.1	0.5	953	17	0.7	
ENMZL	517	17.1	0.9	934	16.7	0.9	
Follicular lymphoma	102	3.4	0.2	298	5.3	0.3	
Mantle cell lymphoma	41	1.4	0	95	1.7	0.1	
Diffuse large B-cell lymphomas	766	25.3	1.2	1470	26.3	1.3	
Burkiitt lymphoma	74	2.4	0.1	89	1.6	0.1	
Other B-cell lymphomas	85	2.8	NA	232	4.1	NA	
Mature T and NK-cell neoplasms	462	15.2	0.8	629	11.3	0.6	
Extranodal NK/T-cell lymphoma, nasal type	153	5.1	0.3	212	3.8	0.2	
Angioimmunoblastic T-cell lymphoma	45	1.5	0	102	1.8	0.1	
Anaplastic large cell lymphoma	60	2	0.1	66	1.2	0.1	
PTCL, NOS	108	3.6	0.2	110	2	0.1	
Other T-cell lymphomas	88	2.9	NA	126	2.3	NA	

ENMZL = extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, NA = not available, PTCL, NOS = peripheral T cell lymphoma, not otherwise specified.

Comparison with Nationwide	studies in Korea	i performed p	previously.
----------------------------	------------------	---------------	-------------

	Nationwide study <sup>1</sup>	Nationwide study <sup>2</sup>	Nationwi	de Study <sup>3</sup>	Present study		
Diagnosis	1995–1996 (n=1548) (%) <sup>12</sup>	2005–2006 (n=3998) (%) <sup>18</sup>	1999–2006 (n=30946) (%) <sup>8</sup>	2007–2012 (n=35002) (%) <sup>8</sup>	1997–2006 (n=3024) (%)	2007–2016 (n=5591) (%)	
Hodgkin lymphoma	5.3	4.6	4.0	4.0	3.4	4.0	
Non-Hodgkin lymphoma	94.7	95.4	96.0	96.0	96.6	96	
Precursor cell neoplasm	3.3	3.8	13.2	9.5	13.1	10.0	
Mature B-cell NHL	70.3	72.8	59.0	69.7	68.2	74.8	
Mature T/NK-cell NHL	20.9	18.8	9.5	10.5	15.2	11.3	
Undetermined type	0.2	0	14.3	6.3	0	0	
Subtype of NHL							
Plasma cell neoplasm	1.1	0.6	15.9	17.9	14.1	17.0	
Extranodal MZL	15.7	18.1	7.1	12.9	17.1	16.7	
Mantle cell lymphoma	1.4	2.3	1.0	1.2	1.4	1.7	
Follicular lymphoma	5.9	2.8	2.1	2.5	3.4	5.3	
DLBCL	41.0	40.7	28.7	30.8	25.3	26.3	
Burkitt lymphoma	1.0	1.9	1.4	1.6	2.4	1.6	
Extranodal NKTCL	8.3	6.0	NA	NA	5.1	3.8	
PTCL, NOS	8.9	6.0	NA	NA	3.6	2.0	
Angioimmunoblastic TCL	1.0	1.6	NA	NA	1.5	1.8	
ALCL	1.5	3.0	NA	NA	1.5	1.8	

ALCL = anaplastic large cell lymphoma, DLBCL = diffuse large B cell lymphoma, MZL = marginal zone lymphoma, NA = not available, NHL = non-Hodgkin lymphoma, NKTCL = NK/T cell lymphoma, PTCL, NOS = peripheral T cell lymphoma, not otherwise specified, TCL = T cell lymphoma.

2001–2006 and 2004–2008, respectively, our cohort showed a markedly lower proportion of T/NK cell neoplasm (11.3% vs 25.5% and 26.4%, respectively). The frequency of extranodal NK/T cell lymphoma was highest in China (11%) followed by our institution (3.8%) and Japan (1.6%). When comparing our data for 2007–2016 with that from the USA in 2016, our cohort showed a similar frequency of Hodgkin lymphoma (4.0% vs 6.2%), diffuse large B cell lymphoma (26.3% vs 20.2%), and plasma cell neoplasms (17% vs 19%), but markedly lower proportions of CLL/SLL (1.9% vs 15.3%) and follicular lymphoma (5.3% vs 10.2%) and higher proportions of T/NK cell lymphoma (11.3% vs 6.1%) and ENMZL (16.7% vs 3.2%) (Table 4).

## 4. Discussion

The etiology of malignant lymphoma is multifactorial, including genetic factors, infectious agents, autoimmune diseases, and socioeconomic factors. The International Lymphoma Epidemiology Consortium (InterLymph) project identified numerous environmental, lifestyle, medical, and genetic risk factors by examining pooled studies of epidemiological surveys and single nucleotide polymorphisms.<sup>[21]</sup> Family history of hematologic malignancy, autoimmune diseases, atopic conditions, lifestyle factors (e.g., smoking, alcohol, anthropometric measures, use of hair dye), and sun exposure are associated with non-Hodgkin's lymphoma risk.<sup>[22–24]</sup> These studies also revealed etiologic commonality and heterogeneity among non-Hodgkin's lymphoma

#### Table 4

Comparison of	subtype	frequency	with the	data	from	other	countries.
---------------	---------	-----------	----------	------	------	-------	------------

Subtypes	Japan 2001–2006		China 2004–2008		US 2016		Present study 2007–2016	
Total	n=2260	%	n=4638	%	n=136960	%	n=5591	%
Hodgkin lymphoma	166	7.4	399	8.6	8500	6.2	225	4.0
Precursor neoplasm	20	0.9	174	3.8	6000	4.4	557	10.0
Mature B-cell neoplasm	1474	65.2	3012	64.9	108,040	78.9	4180	74.8
DLBCL	747	33.1	1680	36.2	27,650	20.2	1470	26.3
Plasma cell neoplasms	13	0.6	233	5	25,980	19.0	953	17.0
CLL/SLL	32	1.4	173	3.7	20,980	15.3	109	1.9
Follicular lymphoma	413	18.3	135	2.9	13,960	10.2	298	5.3
LPL	5	0.2	16	0.3	2330	1.7	44	0.8
ENMZL	95	4.2	355	7.7	4450	3.2	934	16.7
Burkitt lymphoma	15	0.7	47	1	1480	1.1	89	1.6
Mantle cell lymphoma	61	2.7	113	2.4	3320	2.4	95	1.7
T/NK-cell neoplasm	576	25.5	1227	26.4	8380	6.1	629	11.3
ENKTL, nasal type	35	1.6	509	11	190	0.1	212	3.8
PTCL, NOS	102	4.5	182	3.9	1660	1.2	110	2.0
Mycosis fungoides	41	1.8	6	0.1	1620	1.2	30	0.5
Adult T-cell leukemia/lymphoma	226	10.0	1	0	180	0.1	1	0

CLL/SLL = chronic lymphocytic leukemia/small lymphocytic lymphoma, DLBCL = diffuse large B-cell lymphoma, ENKTL = extranodal NK/T-cell lymphoma, ENMZL = extranodal marginal zone lymphoma of MALT, LPL = lymphoplasmacytic lymphoma, PTCL, NOS = peripheral T-cell lymphoma, not otherwise specified.

risk subtypes. Family history of hematologic malignancy, autoimmune diseases, atopic conditions, and alcohol consumption are associated with risk or prevention across several subtypes.<sup>[21]</sup> Eczema, T cell-activating autoimmune diseases (e.g., celiac), and cigarette smoking were more strongly associated with risk of PTCL and/or mycosis fungoides/Sezary syndrome, whereas hepatitis V virus infection, blood transfusion, and B cell-activating autoimmune disease were more strongly associated with B cell lymphomas.<sup>[25]</sup>

According to nationwide studies, malignant lymphoma in Korea is characterized by a lower frequency of Hodgkin lymphoma, follicular lymphoma, and CLL/SLL compared with Western populations.<sup>[12,18]</sup> Previous study from United States analyzing incidence rate differences of malignant lymphoma by birthplace and acculturation demonstrated that the incidence rates were significantly lower in foreign-born Asian than US-born Asian patients for certain lymphoma subtypes, specifically CLL/ SLL, follicular lymphoma, and nodular sclerosis Hodgkin lymphoma. This data strongly suggests a role of environmental factors that influence the risk of FL and CLL/SLL,<sup>[26]</sup> while risk variants identified by genome-wide association study does not exclude a role for genetic susceptibility to follicular lymphoma and CLL/SLL.<sup>[27,28]</sup> Infectious agents are important factors in the characterization of lymphomas in Koreans, particularly the higher incidence of EBV-positive extranodal NK/T cell lymphoma might be associated with primary EBV infection at early childhood and higher prevalence of EBV infection. In one study reported in 1994, 90% of children aged 7-9, and 100% of children aged 10-15 years had EBV antibodies.<sup>[29]</sup> High frequency of gastric MZL appears to ascribe to a high prevalence of Helicobacter pylori infection among Koreans.<sup>[30,31]</sup>

As domestic socioeconomic and health care conditions have improved markedly over the last four decades in Korea, there have been changes in the epidemiology of infectious diseases, the population structure by age, and lifestyles. Due to significantly increased life expectancy, the elderly population has also increased dramatically, while the birth rate has been steadily declining. Obesity is increasing every year, and this has become a very important public health issue.<sup>[32]</sup> The seroprevalence of EBV infection in young adults and adolescents was 100% in 1994, but decreased to 87.2% in 2007.<sup>[33]</sup> Likewise, the seroprevalence of H. pylori in healthy adults has gradually decreased, from 66.9% in 1998 to 54.4% in 2011.<sup>[34]</sup> Although well-planned epidemiologic evaluation correlating lymphoma subtypes and etiologic factors has not been carried out in Korea, we can expect that such health and socioeconomic changes would result in changes in the subtypes of lymphoid neoplasms.

The occurrence of cancer is increasing because of population growth and aging, as well as increasing prevalence rates of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development.<sup>[35]</sup> In the USA, lymphoma incidence rates increased steadily during the 1970s and 1980s, leveled off in the 1990s, and have declined slightly (0.3% per year) since 2001 in females and since 2004 in males.<sup>[36,37]</sup> In Korea, patients with malignant lymphoid neoplasm are continuously increasing. According to KNCIDB data, registered patients with lymphoid neoplasm (in 2002–2012) increased 1.84 times (3606 in 2002 and 6638 in 2012). The overall age-standardized incidence rates of all lymphoid malignancies increased from 6.9 to 9.9, with an annual percentage change of 3.2% between 1999 and 2012.<sup>[8]</sup>

Accordingly, lymphoma patients in our cohort increased 1.85 times during the 20-year study period. The most notable change during this period was an increase in B cell lymphoma and a relative decrease in T cell lymphoma and precursor lymphoid neoplasm. This change may be due to an increase in population age as well as other unknown factors. In support of this speculation, the median age of lymphoma patients in our cohort increased from 51 years in 1997–2006 to 56 years in 2007–2016. Increased plasma cell neoplasm was also notable, and an aging population and increasing body size may partly explain this increase. Obesity, a risk factor for plasma cell neoplasms, is steadily increasing in Korea.<sup>[32,38]</sup> Other B cell lymphomas, including follicular lymphoma and mantle cell lymphoma, increased significantly. In addition to these changes associated with an increased aging population, our data show that infectious agent-associated lymphoma is decreasing. Extranodal NK/T cell lymphoma is a prototype of EBV-associated disease and virtually all tumor cells are infected by EBV. EBV-associated lymphoid malignancy is more prevalent in certain parts of Asia and Latin America, strongly suggesting genetic or environmental predisposition in the development of EBV-positive lymphoma. As noted, as socioeconomic conditions have improved in Korea, the age of first EBV infection is increasing like Western countries.<sup>[33,39]</sup> EBV infection in young children whose immune system has not matured can lead to diseases such as chronic active EBV infection when they have genetic susceptibility. Although the role of EBV in the pathogenesis of extranodal NK/T cell lymphoma is not well known, the epidemiologic distribution of chronic active EBV infection and NK/T cell lymphoma is similar, suggesting that similar mechanisms may play a role in the development of NK/T cell lymphoma. Considering that, the decrease in the relative frequency of extranodal NK/T cell lymphoma in our cohort may be explained by the increasing of the age of first EBV infection, although we cannot exclude the influence of other risk factors. On the other hand, ENMZL has an etiologic relationship with H. pylori, autoimmune disease, and other infectious agents. Decrease in H. pylori infection in the general population may contribute to slowing the increase in ENMZL.

Malignant lymphoma is generally more common in male, but some subtypes have a female predominance. Typically, mediastinal large B cell lymphomas and subcutaneous panniculitis-like T cell lymphoma occur in male patients more frequently, which is also the case with our cohort.<sup>[40]</sup> In this study, low grade follicular lymphoma was more prevalent in female but high grade lymphoma in males. In Western population, the vast majority of follicular lymphoma is of low grade and has a male to female ratio of 1:1.7.<sup>[41,42]</sup> High grade follicular lymphoma by the 2008 WHO classification is heterogeneous lymphoid neoplasm which includes large B cell lymphoma with IRF-4 rearrangement, pediatric follicular lymphoma, and follicular lymphoma, grade 3B.<sup>[43]</sup> It is different from low grade follicular lymphoma in the clinical, genetics, and even in the gender distribution. Extranodal marginal zone lymphoma has been known to show an equal distribution of gender or slight female predominance.<sup>[44]</sup> In our cohort, extranodal marginal zone lymphoma affected more females than males and the gastric marginal zone lymphoma accounted for 61% of cases. Extragastric marginal zone lymphomas of the thyroid and salivary gland associated with autoimmune disease affect mainly female patients.<sup>[45]</sup> In this study marginal zone lymphoma involving thyroid and salivary gland accounted for only a minority of cases.

The main drawback of this study is that the data are based on the patients from a single institution, so it is doubtful whether the results could reflect the nationwide data. In Korea, patients with lymphoma tend to gather in 4-5 large hospitals located in Seoul from each province, and Samsung Medical Center is one of these large hospitals. Therefore, the distribution of patients is not biased toward any particular type and may be consistent with the distribution of patients across the country. In addition, this study has several strengths compared with other previous studies. It included all lymphoid neoplasms in the liquid phase as well as solid phase, study subjects are the large-scale population and covers approximately 10% of all lymphoma patients in the country, lymphoma classification was performed based on sufficient ancillary studies by experienced hematopathologists, and the data is that of the most up-to-date. Despite the weaknesses of this study, these strengths will add value for future reference. In summary, we report herein the changing trends in the proportion of subtypes of malignant lymphoma in Korea and discuss the relationships with the population structure based on age and the prevalence of infectious agents. Considering the complexities of lifestyles and genetic factors that impact lymphomagenesis, the risk factors noted here may be somewhat superficial. Systematic epidemiological studies exploring these risk factors are needed to predict future changes in lymphoma frequency and to establish management strategies.

#### Acknowledgments

We thank Dr. In-Suk Shon for statistical analysis.

## **Author contributions**

Data curation: Takuya Takayama, Junhun Cho, Seok Jin Kim, Won Seog Kim, Howe J. Ree.

Funding acquisition: Young Hyeh Ko.

Methodology: Jongmin Sim.

Resources: Junhun Cho.

Supervision: Young Hyeh Ko.

Visualization: Young Hyeh Ko.

Writing - original draft: Jongmin Sim.

Writing - review & editing: Young Hyeh Ko.

Jongmin Sim: 0000-0002-7106-1279.

Jongmin Sim orcid: 0000-0002-7106-1279.

#### References

- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375–90.
- [2] Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019–32.
- [3] National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program, Cancer Statistics. Reports on Cancer. Cancer Stat Facts. Available at: https://seer.cancer.gov/statfacts. Accessed October 20, 2018.
- [4] Park HJ, Park EH, Jung KW, et al. Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol 2012;47:28–38.
- [5] Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 2018;50:303–16.
- [6] Jung KW, Won YJ, Kong HJ, et al. Prediction of cancer incidence and mortality in Korea, 2018. Cancer Res Treat 2018;50:317–23.

- [8] Lee H, Park HJ, Park EH, et al. Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res Treat 2018;50:222–38.
- [9] Bassig BA, Lan Q, Rothman N, et al. Current understanding of lifestyle and environmental factors and risk of non-hodgkin lymphoma: an epidemiological update. J Cancer Epidemiol 2012;2012:978930.
- [10] Kleiner J. Korea: A Century of Change. Singapore: World Scientific; 2001.
- [11] Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's lymphoma classification project. Ann Oncol 1998;9:717–20.
- [12] Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998;83:806–12.
- [13] The world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000;50:696–702.
- [14] Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005;16:206–14.
- [15] Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–30.
- [16] Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4638 cases according to the World Health Organization classification. Am J Clin Pathol 2012;138:429–34.
- [17] Yoon SO, Suh C, Lee DH, et al. Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Am J Hematol 2010;85:760–4.
- [18] Kim JM, Ko YH, Lee SS, et al. WHO classification of malignant lymphomas in Korea: report of the third nationwide study. Korean J Pathol 2011;45:254–60.
- [19] Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases. Pathol Int 2008;58:174–82.
- [20] Langerak AW, Groenen PJ, Brüggemann M, et al. EuroClonality/ BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012;26:2159–71.
- [21] Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr 2014;2014: 130–44.
- [22] Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 109:3479–88.
- [23] Morton LM, Hartge P, Holford TR, et al. Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph). Cancer Epidemiol Biomarkers Prev 2005;14:925–33.
- [24] Wang SS, Flowers CR, Kadin ME, et al. Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr 2014;2014:66–75.
- [25] Chihara D, Nastoupil LJ, Williams JN, et al. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther 2015;15:531–44.
- [26] Clarke CA, Glaser SL, Gomez SL, et al. Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation. Cancer Epidemiol Biomarkers Prev 2011;20:1064–77.
- [27] Berndt SI, Skibola CF, Joseph V, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet 2013;45:868–76.
- [28] Conde L, Halperin E, Akers NK, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 2010;42:661–4.
- [29] Oh SH, Lee YA, Moon WY, et al. Prevalence of Epstein–Barr virus (EBV) antibody in Korean children. J Korean Pediatr Soc 1994;37:804–11.

- [30] Malaty HM, Kim JG, Kim SD, et al. Prevalence of *Helicobacter pylori* infection in Korean children: inverse relation to socioeconomic status despite a uniformly high prevalence in adults. Am J Epidemiol 1996; 143:257–62.
- [31] Yim JY, Kim N, Choi SH, et al. Seroprevalence of *Helicobacter pylori* in South Korea. Helicobacter 2007;12:333–40.
- [32] Bae NK, Kwon IS, Cho YC. Ten year change of body mass index in Korean: 1997~2007. Korean J Obes 2009;18:24–30.
- [33] Kang CI, Choi CM, Park JT, et al. Seroprevalence of Epstein–Barr virus infection in young men of South Korea. Infect Chemother 2007;39:93–4.
- [34] Kim SY. Time trends in the prevalence of *Helicobacter pylori* infection and future directions in Korea. Korean J Helicobacter Up Gastrointest Res 2016;16:123–8.
- [35] Cronin KA, Lake AJ, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 2018;124: 2785–800.
- [36] Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66:443–59.
- [37] Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute; 2015.
- [38] Teras LR, Kitahara CM, Birmann BM, et al. Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol 2014;166:667–76.

- [39] Balfour HHJr, Sifakis F, Sliman JA, et al. Age-specific prevalence of Epstein–Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis 2013; 208:1286–93.
- [40] Goyal A, Goyal K, Bohjanen K, et al. Epidemiology of primary cutaneous gamma/delta T-cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma in the United States from 2006–2015: a surveillance, epidemiology, and end results-18 analysis. Br J Dermatol 2019;181: 848–50.
- [41] A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
- [42] Wahlin BE, Yri OE, Kimby E, et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol 2012;156:225–33.
- [43] Steven H, Swerdlow EC, Harris NL, et al. World Health Organisation Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edLyon: International Agency for Research on Cancer; 2008.
- [44] Khalil MO, Morton LM, Devesa SS, et al. Incidence of marginal zone lymphoma in the United States, 2001–2009 with a focus on primary anatomic site. Br J Haematol 2014;165:67–77.
- [45] Kiesewetter B, Lukas J, Dolak W, et al. Gender aspects in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue: does sex matter? Oncology 2016;91:243–50.